Axsome gets FDA review for Auvelity in Alzheimer’s agitation

Axsome Therapeutics (AXSM) stock gains as the FDA grants priority review to expand its depression drug Auvelity for Alzheimer’s disease agitation. Read more here.

You will be redirected in 10 seconds.